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Short-term antibiotic treatment profoundly affects the intestinal microbiota, which may lead to sustained changes in microbiota composition.
Probiotics may restore such a disturbance. The objective of the present study was to investigate the effect of a multispecies probiotic on the
faecal microbiota during and after antibiotic intake in patients with a history of frequent antibiotic use. In this randomised, placebo-controlled,
double-blind study, thirty chronic obstructive pulmonary disease (COPD) patients treated with antibiotics for a respiratory tract infection received
5 g of a multispecies probiotic or placebo twice daily for 2 weeks. Faecal samples were collected at 0, 7, 14 and 63 d. Changes in the composition
of the dominant faecal microbiota were determined by PCR-denaturing gradient gel electrophoresis (DGGE). Changes in bacterial subgroups were
determined by quantitative PCR and culture. Bowel movements were scored daily according to the Bristol stool form scale. During and after
antibiotic treatment, DGGE-based similarity indices (SI) were high ($84 %) and band richness was relatively low, both remaining stable over
time. No difference in SI was observed between patients with and without diarrhoea-like bowel movements. The multispecies probiotic had a
modest effect on the bacterial subgroups. Nevertheless, it affected neither the composition of the dominant faecal microbiota nor the occurrence
of diarrhoea-like bowel movements. The dominant faecal microbiota was not affected by antibiotics in this COPD population, suggesting an
existing imbalance of the microbiota, which may also have contributed to the lack of effect by probiotic intake.
Probiotics: Antibiotics: PCR-denaturing gradient gel electrophoresis: Intestinal microbiota: Bowel movements
In recent years, our knowledge on the composition of the
human intestinal microbiota has greatly improved with the
introduction of molecular techniques based on 16S rRNA
gene sequences, confirming that the microbiota is subject
specific and comprises a complex and very diverse bacterial
ecosystem of which most species belong to previously
unknown (i.e. uncultivated) lineages(1 – 3). In healthy indi-
viduals, the dominant intestinal microbiota is found to be
relatively stable over time(1,4 – 7). However, in various
populations it has been demonstrated that antibiotic intake
can cause a marked disturbance of the intestinal microbiota
as they not only affect pathogens but also the indigenous
microbiota, which may result in antibiotic-associated
diarrhoea (AAD). It is widely assumed that this disturbance
is short-term but recently also medium and long-term
disturbances in (specific) bacterial populations have been
described(8 – 10). However, there are chronically ill patients,
such as patients suffering from chronic obstructive pulmonary
disease (COPD), who receive frequent antibiotic therapy.
COPD is characterised by a progressive airflow obstruction,
associated with a chronic inflammatory response in the
airways consisting mainly of neutrophils, CD8þT-cells and
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macrophages(11,12). Acute exacerbations play an important
role in the clinical course of the disease and are an important
cause of morbidity and mortality(13,14). Although the under-
lying pathogenic mechanisms are poorly understood, antibiotic
therapy is frequently prescribed. The effects of such fre-
quent antibiotic use on the intestinal microbiota are, to our
knowledge, not known.
The intestinal microbiota plays an important role in human
physiology, being involved in gut maturation, colonisation
resistance, several metabolic processes, regulation of intestinal
epithelial proliferation and modulation of the mucosal and
systemic immune response(15 – 18). Based on this, probiotics are
often given during and after antibiotic intake and beneficial
effects have been observed in the prevention and treatment
of AAD(19 – 22). Therefore, in the present study a multispecies
probiotic was given containing nine different probiotic strains
selected on the basis of their in vitro ability to inhibit
growth of Clostridium spp., in vitro survival of gastrointestinal
passage(23) (i.e. low pH (2·5) as well as bile and digestive
enzymes (pancreatin and pepsin)) and the absence of acquired
antibiotic resistance. Moreover, a combination of strains were
selected in which strain-specific properties were chosen to
be additive or synergistic and mutual inhibition was absent.
In addition, we previously showed that in healthy volunteers
the intake of this multispecies probiotic during and after
amoxycillin intake has no adverse effects and affects the
faecal microbiota resulting in a faster restoration toward the
pre-antibiotic state(10).
The aim of the present study was to assess the disturbance
of the dominant faecal microbiota and the possible restoration
by a multispecies probiotic in patients with COPD treated
with antibiotics for an acute exacerbation. Moreover, the
effect on specific bacterial subgroups, using both culture-
dependent and molecular based techniques, bowel habits, the
incidence of antibiotic resistance, endotoxins and pH was
also studied.
Methods
Subjects
Forty-five patients, 18–80 years of age, with moderate to
severe COPD admitted to the Centre for Integrated Rehabi-
litation of Organ Failure (Horn, The Netherlands) for a
comprehensive interdisciplinary pulmonary rehabilitation
program were included in the study. Patients had to have
an acute exacerbation of COPD, which according to the
Anthonisen criteria(24) should be treated by a 7 d antibiotic
regimen, as judged by the physician in charge. Exclusion
criteria were: immune-compromised subjects or treatment
with immune-suppressive medication other than for COPD,
pregnancy, lactation, hypersensitivity to the commonly
prescribed antibiotics, pre-existing bowel pathology (including
irritable bowel syndrome, inflammatory bowel disease, diver-
ticulitis and cancer) and diarrhoea or constipation (in the last
3 d before inclusion). When using doxycycline maintenance
therapy, corticosteroids or gastric acid inhibitors, patients
had to be on stable medication for more than 2 weeks.
Furthermore, patients were not allowed to use (1) laxatives
and anti-diarrhoea medication in the 2 weeks before the
start of the study and during the study; (2) regular pro- and
prebiotic intake in the 2 weeks before the start of the study
and during the study. Finally, ex-smokers had to have quitted
smoking for at least 2 weeks before the start of the study.
The present study was conducted according to the guide-
lines laid down in the Declaration of Helsinki and all pro-
cedures involving patients were approved by the Medical
Ethics Committee of the University Hospital Maastricht, The
Netherlands. Written informed consent was obtained from
all the patients.
Study design
The study was executed according to a parallel, randomised,
placebo-controlled, double-blind design. The total duration
of the intervention and follow-up period was 63 d. All the
patients were prescribed a 7 d antibiotic treatment and were
randomised to receive either 5 g of a multispecies probiotic,
Ecologicw AAD, or placebo twice daily for 14 d starting sim-
ultaneously with antibiotic treatment. This resulted in three
time periods defined as: days 1–7, ‘the antibiotic/probiotic
period’ in which all patients received a 7 d antibiotic treatment
in combination with either probiotic or placebo; days 8–14,
‘the probiotic only period’ in which patients received either
probiotic or placebo; days 15–63, ‘the post-treatment
follow-up period’. The antibiotic treatment was given accord-
ing to the physician’s instructions (care as usual). The time
between antibiotic and probiotic intake had to be at least
2 h. Fresh faecal samples were collected on days 1 (the first
sample patients were able to produce after inclusion), 7, 14
and 63. On the same day, a questionnaire was filled out includ-
ing the clinical COPD questionnaire(25), questions on bowel
movements (stool frequency and consistency (ranging from
‘1’, hard lumps, to ‘7’, completely watery) according to the
Bristol stool form scale(26)), use of pre- and probiotics, other
medication taken, change of eating habits and compliance.
In addition, a short questionnaire on bowel habits and side-
effects (nausea, abdominal cramps, bloating, flatulence or
other) had to be completed daily during probiotic/placebo
intake. Moreover, this questionnaire was used to determine
diarrhoea-like defecation defined as a defecation frequency
$3/d and/or a faecal consistency (on the Bristol stool form
scale) $5/d for at least 2 d.
Probiotic
The multispecies probiotic (Ecologicw AAD) and the
placebo were kindly provided by Winclove Bio Industries,
Amsterdam, The Netherlands. Ecologicw AAD consists of
nine different bacterial species at 108 colony forming units/g
each, 5 % mineral mix and 15 % Raftilosew Synergy1. All
strains are deposited in the Dutch Dairy Institute (NIZO,
Ede, The Netherlands) culture collection and are characterised
with (GTG)5-PCR fingerprinting as well as further finger-
printing using BOX-A1R and OPY11 primers, followed by
SSU (16S)-rRNA sequence analysis (Bifidobacterium bifidum
NIZO 3804, Bifidobacterium lactis NIZO 3680 (formerly
known as Bifidobacterium longum), Enterococcus faecium
NIZO 3886, Lactobacillus acidophilus NIZO 3678 and NIZO
3887, Lactobacillus paracasei NIZO 3672, Lactobacillus
plantarum NIZO 3684, Lactobacillus rhamnosus NIZO 3689
and Lactobacillus salivarius NIZO 3675). Individual probiotic
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strains carry the European Union qualified presumption of
safety and all the study products (both probiotic and placebo)
were prepared under good manufacturing process conditions.
Each patient consumed sachets containing 5 g Ecologicw
AAD or placebo twice daily for 2 weeks. Sachets had
to be dissolved in lukewarm water, left for 10 min, stirred
and thereafter ingested. Both probiotic and placebo were
packaged in identical, numbered sachets. The placebo sachets,
indistinguishable in colour, smell and taste also contained
5 % mineral mix and 15 % Raftilosew Synergy1 but contained
maizestarch instead of the probiotic bacteria. In a pilot
study with five healthy volunteers, the 2-week consumption
of 1·5 g Raftilosew Synergy1 per day affected neither bifido-
bacterial communities (using PCR-denaturing gradient gel
electrophoresis (DGGE) and most probable number-PCR)
nor faecal lactic acid bacteria and lactobacilli counts
(CJM Koning, D Jonkers, E Stobberingh, H Smid and
R Stockbru¨gger, unpublished results).
Sample processing
Faecal samples were brought to the laboratory within 12 h
after defecation and divided into three portions: (1) 10 g
were centrifuged at 47 000 g for 2 h at 4 8C to obtain faecal
water, which was frozen immediately in twofold at 2808C
for analysis of endotoxin concentrations and determination
of pH; (2) 5 g were diluted (1:4) with peptone water (Oxoid
CM9, Basingstoke, Hants, UK) supplemented with cysteine
(2·1 mM) and glycerol (30 %) and used immediately for
bacterial culture; (3) the remaining faecal sample (1–15 g)
was frozen directly at 2208C for molecular analysis.
DNA extraction
DNA was isolated from approximately 0·1 g of frozen
faeces, using the FastDNA SPIN Kit for Soil (Qbiogene,
Carlsbad, CA, USA) and a FastPrep Instrument (FP120,
Savant Instruments, Farmingdale, NY, USA) following
instructions of the manufacturer. Extracted DNA was checked
by agarose gel (1·2 % (w/v)) electrophoresis in the presence
of ethidium bromide.
PCR amplification, denaturing gradient gel electrophoresis
analysis and quantitative PCR
Total bacterial profiles from all the samples were analysed by
DGGE of 16S rRNA gene fragments amplified by PCR with
primers 0968-f-GC and 1401-r as described previously(27,28).
Amplicons generated by PCR were separated by DGGE
in 8 % polyacrylamide gels using a DCode TM system
(Bio-Rad Laboratories, Hercules, CA, USA) as described
elsewhere(28,29). For the separation of amplicons, gradients
of 40–50 % were used (100 % denaturing solution was defined
as 7 M-urea and 40 % formamide). Gels were stained with
AgNO3
( 30). The DGGE gels were analysed using Bionumerics
4.0 (Applied Maths BVBA, Sint-Martens-Latem, Belgium).
Following normalisation of gel images using markers loaded
on either side and in the central lane of each gel, bands
were defined for each sample using the bands searching
algorithm within the program. Corresponding densitometric
curves were used for a manual check of band definition, and
bands with ,1 % of the total area of all bands were omitted
from further analysis(31). The similarity of the DGGE profiles
(expressed as similarity indices (SI)) with baseline (day 0;
e.g. 0–7, 0–14, etc.) and between consecutive days
(e.g. 0–7, 7–14, etc.) was determined by calculating a Dice
correlation coefficient (band based) according to the principle
of moving window correlation(32).
Quantitative detection of total bacteria, lactobacilli and
bifidobacteria was performed using an iCycler IQ real-time
detection system associated with the iCycler optical system
interface software version 2.3 (Bio-Rad, Veenendaal,
The Netherlands). Total bacterial 16S rRNA gene copies were
quantified with primers Bact-1369-f and Prok-1492-r(33),
lactobacilli were quantified using primers LactoF and
LactoR(34) and bifidobacteria by primers Bif 164-f and
662-r(35) as described previously(36).
Bacteriological culture
Microbiological analysis of the faecal samples was deter-
mined as previously described(37). Briefly, tenfold serial
dilutions of the faecal dilution were made in physiological
saline (0·85 %) with cysteine–HCl (0·05 %), and 40ml of
these dilutions were inoculated on agar plates to culture and
count total (facultative) aerobic bacteria (blood agar, Oxoid
CM 271), enterobacteria (methylthionium chloride agar,
Oxoid CM69), enterococci (KF-streptococcus agar, Oxoid
CM701), total (facultative) anaerobic bacteria (fastidious
anaerobic agar, Laboratory M LabGo), Bacteroides spp.
(Bile Esculin agar, Becton Dickinson 287920), lactobacilli
(LAMVAB agar(38)) and yeasts (Sabouraud GM þ C agar,
Becton Dickinson 254041). Escherichia coli and enterococci
isolates were identified using standard biochemical tests(39)
and stored at 2808C for susceptibility testing.
Table 1. Patient characteristics*
(Mean values and standard deviations)
Probiotic (n 17) Placebo (n 13)
Mean SD Mean SD
Sex m/f (n) 12/5 7/6
Age (years) 59·9 13·3 63·4 7·4
Current smokers (n) 3 1
BMI (kg/m2) 27·1 6·6 27·4 4·9
FFMI (kg/m2) 17·7 2·6 18·4 5·7
FEV1 (% pred) 43·0 20·3 40·8 28·0
FVC (% pred) 84·7 17·1 75·6 19·5
CCQ total score 3·0 0·7 3·25 0·9
Antibiotic treatments
in previous year
2·9 2·6 3·3 2·1
Use of pre- and probiotics
before the study (n)
0 1†
Compliance‡ probiotic/placebo
intake (%)
98·1 4·6 99·7 1·0
m/f, Male/female; FFMI, fat free mass index; FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; CCQ, clinical chronic obstructive pulmonary dis-
ease questionnaire; dd, developmentally disabled.
* There was no significant difference between the probiotic and the placebo groups
(P . 0·05).
† Yakult 1 dd.
‡ Compliance is self-reported.
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Susceptibility testing
Antimicrobial susceptibilities (as minimal inhibitory concen-
tration values) for the E. coli and enterococci isolates were
determined using the microbroth dilution method with
cation-adjusted Mueller–Hinton broth II (Becton, Dickinson
and Company, Sparks, MD, USA) according to the Clinical
and Laboratory Standards Institute (formerly the National
Committee for Clinical Laboratory Standards) guidelines as
described previously(40). Microtitre plates containing freeze-
dried antibiotics were obtained from MCS Diagnostics B.V.
(Swalmen, The Netherlands) after quality testing by the
manufacturer and a guaranteed shelf-life of about 1 year.
The minimal inhibitory concentration was defined as the
lowest concentration showing no growth in the microtitre
plates after 18 h of incubation at 378C. E. coli ATCC 35 218
and ATCC 25 922 and Escherichia faecalis ATCC 29 212
were used as quality control reference strains.
Endotoxin and pH
The endotoxin (i.e. lipopolysaccharide) concentration was
determined in faecal water using the Limulus amoebocyte
lysate endochrome technique (Endosafe, end-point chromo-
genic analysis endochrome test kit; Charles River, Kent,
UK), according to the manufacturer’s specifications under
pyrogen-free conditions. Pyrogen-free water was used to
dilute the faecal samples, the test solutions, and was used
as a negative control. The detection range of the assay
was 0·015–0·12 endotoxin units/ml (9 endotoxin units/ng).
Concentration of faecal endotoxin was expressed as nanogram
of endotoxin per ml of faecal water. The pH of faecal water
was determined using a PHM standard pH meter with a
PHC3006 electrode (Radiometer Nederland B.V., Zoetermeer,
The Netherlands).
Statistics
The treatment allocation was concealed to all investigators and
volunteers, until the study had been completed and all the
analyses had been performed.
The primary outcome of the present study was to assess
the restoration of the dominant intestinal microbiota after
antibiotic treatment in probiotic- and placebo-treated patients
by PCR-DGGE. Based on data from our previous study
in healthy volunteers(10), it was estimated that fourteen
volunteers per treatment group would provide a 80 % power
to detect a 20 % increase in SI after disturbance of antibiotic
intake, assuming a variance of 18 % and a two-sided signi-
ficance level of 0·05.
Secondary outcomes were to assess changes in probiotic-
and placebo-treated patients during and after antibiotic
intake in (1) specific bacterial subgroups, using both culture-
dependent and molecular based techniques; (2) bowel habits;
(3) the incidence of antibiotic resistance; (4) endotoxin
concentration and pH. In addition, the disturbance of the
dominant intestinal microbiota in the subjects who develop
AAD compared with those who did not was assessed.
Statistical evaluation of DGGE band richness, quantitative
PCR, culture, endotoxin concentration and pH was carried
out using linear mixed model analysis as described
previously(10,37).
For all other data the nonparametric Mann–Whitney U test
was used for two-group comparisons of independent ordinal
and interval values, while the nonparametric Wilcoxon
signed-ranked test was used for comparison of related ordinal
and interval values. If the data were normally distributed,
the Student’s t-test was used. For dichotomous variables,
Pearson’s x 2-test was applied to test for differences between
groups. All the tests were conducted using SPSS version
11.0 (SPSS, Inc., Chicago, IL, USA) and a P value below
0·05 was considered statistically significant.
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Fig. 1. Total bacterial band richness (mean (SEM) no. of bands) obtained
from denaturing gradient gel electrophoresis profiles of probiotic- (o) and
placebo ( )-treated patients before, during (days 1–7) and after antibiotic
intake.
Table 2. Similarity indices (SI) of the total bacterial profiles in percentages in the probiotic group v. the placebo group compared with
baseline (t ¼ 0) and between consecutive intervals
(Median and range values)
SI (%)
0–7 0–14 0–63 7–14 14–63
Median Range Median Range Median Range Median Range Median Range
Probiotic* (n 17) 90 69–98 87 46–96 88 65–95 90 56–98 90 63–98
Placebo (n 13) 94 44–98 93 45–98 84 39–97 91 69–98 89 55–98
* Within group decrease 0–63 v. 0–7, P,0·05.
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Results
Subjects
From September 2005 to December 2006, forty-five patients
were enrolled of which thirty patients completed the study;
seventeen in the probiotic group and thirteen in the placebo
group. Eleven patients (73 %) discontinued the study in the
first week, three patients (20 %) in the second week and one
patient (7 %) thereafter. The most common reasons for discon-
tinuation included ‘not being able or willing to collect faeces’;
‘perception of the study load as being too demanding consi-
dering the current medical condition’; ‘not liking the taste
of the study product’. Baseline demographics and clinical
characteristics were comparable for both the groups
(Table 1). The antibiotic treatments prescribed for the exacer-
bation were mostly doxycycline and amoxycillin/clavulanic
acid and were also comparable for both the groups. The
mean frequency of antibiotic use was 3·1 (SD 2·4) treatments
in the year before inclusion.
Eight patients in the probiotic group and five patients in
the placebo group (P¼0·72) changed their dietary habits
during the study period, mostly based on medical indication
(energy restriction (n 10), supplementation with nutrient
drinks (n 2), loss of appetite (n 1)). Apart from the exclusion
criteria, patients in both the groups used diverse and extensive
medication mostly belonging to the groups of analgesia, anti-
depressants, antihypertensives, diuretics, sympathicomimetics,
xanthines and parasympathicolytics.
There were no reported adverse events related to the
study product. Compliance was assessed by the self-reported
number of study product (sachets) that was consumed.
Bowel habits
The mean defecation frequency (probiotic, 1·4 (SEM 0·4), 2·0
(SEM 0·4), 1·6 (SEM 0·3); placebo, 1·1 (SEM 0·1), 1·4 (SEM
0·2), 1·6 (SEM 0·3)) and consistency (probiotic, 3·9 (SEM
0·4), 4·5 (SEM 0·3), 4·6 (SEM 0·2); placebo 3·5 (SEM 0·4), 4·2
(SEM 0·4), 4·0 (SEM 0·4)) before antibiotic and probiotic
intake (day 0, i.e. baseline), during the antibiotic/probiotic
period (days 1–7) and during the probiotic only period
(days 8–14), respectively, did not differ significantly between
the probiotic and the placebo groups. In the probiotic group,
the defecation frequency during antibiotic intake was signifi-
cantly higher (2·0 (SEM 0·4)) compared with baseline (1·4
(SEM 0·4); P,0·05). During and 1 week after antibiotic
intake (days 1–14), diarrhoea-like bowel movements were
reported frequently in both the probiotic group (77 %) and
the placebo group (70 %; P.0·05).
PCR-denaturing gradient gel electrophoresis analysis of the
dominant faecal microbiota
DGGE analysis of the dominant faecal microbiota showed
high inter-individual variation in total bacterial profiles
between patients and a mean number of 15·4 bands per
profile (i.e. band richness) at the start of the study (day 0).
No difference in band richness between the probiotic and
the placebo groups or over time within both the groups was
found (Fig. 1).
SI were high and remained stable during and after antibiotic
treatment (Table 2). No effect of probiotic intake was
observed. At day 63, lower SI (compared with baseline)
were found in both the groups, which were only significant
in the probiotic group. Moreover, no association between
the SI of the total bacterial profiles during amoxycillin and
probiotic intakes and the occurrence of diarrhoea-like bowel
movements was observed (data not shown).
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Fig. 2. Quantitative PCR results expressed as mean (SEM) log copies DNA/g
faeces obtained from faeces of probiotic- (o) and placebo ( )-treated
patients before, during (days 1–7) and after antibiotic intake: *P , 0·05.
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Quantitative PCR
No differences in the 16S rRNA gene copy numbers of total
bacteria, lactobacilli or bifidobacteria were observed between
the probiotic and the placebo groups. Within both the groups,
a significant decrease of bifidobacteria was found during
antibiotic intake, which increased again after cessation
(Fig. 2). During probiotic intake (day 14), a small increase
in total bacteria was observed in the probiotic group, which
significantly decreased again after cessation. Moreover, a
significant increase in lactobacilli was observed in the pro-
biotic group (Fig. 2). For all the bacterial species studied,
values on day 63 did not differ significantly from day 0
apart from a decrease in bifidobacteria in the probiotic
group and a decrease in total bacteria in the placebo group
(Fig. 2). To adjust for possible differences in faecal consis-
tency, data were also analysed as 16S rRNA gene copies
per mg faecal protein with similar results compared with the
unadjusted data (data not shown).
Bacteriological culture
No differences in either aerobic or anaerobic cultured-
bacterial species were observed between the probiotic and
the placebo groups (Table 3). However, group-specific differ-
ences were observed over time. During ‘the probiotic only
period (14 d)’, the mean number of faecal enterococci
increased significantly within the probiotic group, returning
to pre-treatment level 7 weeks after cessation (P,0·05;
Table 3). Moreover, within the probiotic group, a significant
decrease was found in enterobacteria (day 7 v. day 0), and
significant increases were observed over time in total aerobes
(days 7 and 14 v. days 0 and 63), Bacteroides spp. (day 14 v.
days 0 and 63) and lactobacilli (days 14 and 63 v. day 7)
(P,0·05). Within both the groups, a significant increase in
yeast was found during antibiotic intake (day 7; Table 3).
For all the bacterial species, in both the groups, bacterial
counts on day 63 did not differ significantly from day 0.
Antimicrobial susceptibility
E. coli isolates were isolated in 47–82 % (probiotic) and
54–69 % (placebo) of the faecal samples and enterococci
were isolated in 77–100 % (probiotic) and 92 % (placebo) of
the faecal samples from the patients at the different points
of time. No significant differences in antibiotic susceptibility
of E. coli and enterococci were observed.
Endotoxin and pH
Mean endotoxin concentrations, expressed as log ng/ml
faecal water, did not differ significantly between groups
and within both groups during the study period (probiotic,
2·5 (SEM 0·1), 2·6 (SEM 0·08), 2·5 (SEM 0·07) and 2·4
(SEM 0·09); placebo, 2·5 (SEM 0·06), 2·5 (SEM 0·09), 2·5
(SEM 0·09), 2·5 (SEM 0·01) at t ¼ 0, 7, 14 and 63, respec-
tively). Also, no significant correlation between the number
of enterobacteria cultured and endotoxin concentration
was found.
Table 3. Numbers of bacteria cultured expressed as log colony-forming units/g faeces
(Mean values with their standard errors)
Day 0 Day 7 Day 14 Day 63
Mean SEM Mean SEM Mean SEM Mean SEM
Total aerobic microbiota
Probiotic* 7·4 0·2 8·2 0·3 8·4 0·2 7·4 0·3
Placebo 7·5 0·4 7·3 0·3 7·5 0·3 7·4 0·3
Enterobacteriaceae
Probiotic† 6·5 0·4 4·6 0·8 5·3 0·7 5·3 0·6
Placebo 5·5 0·7 4·1 0·8 4·5 0·8 5·9 0·6
Enterococci
Probiotic‡ 5·5 0·4 5·8 0·5 7·1 0·4 4·9 0·5
Placebo 5·3 0·5 6·4 0·4 5·7 0·6 5·4 0·4
Total anaerobic microbiota
Probiotic 9·5 0·2 9·1 0·5 9·1 0·5 9·2 0·2
Placebo 9·5 0·1 9·5 0·2 9·1 0·7 9·8 0·1
Bacteroides spp.
Probiotic§ 7·2 0·3 7·6 0·4 8·1 0·2 7·2 0·3
Placebo 7·0 0·5 7·9 0·2 7·8 0·3 7·8 0·2
Lactobacilli
Probiotick 5·3 0·4 5·1 0·5 6·0 0·5 5·9 0·5
Placebo 5·3 0·6 5·1 0·4 5·7 0·5 5·6 0·5
Yeast
Probiotic{ 2·8 0·4 3·9 0·4 3·2 0·3 3·2 0·4
Placebo** 2·2 0·4 3·2 0·4 2·9 0·4 2·2 0·3
* Within group increase t ¼ 7/14 v. t ¼ 0/63, P,0·05.
† Within group decrease t ¼ 7 v. t ¼ 0, P,0·05.
‡ Within group increase t ¼ 14 v. t ¼ 0/7/63, P,0·05.
§ Within group increase t ¼ 14 v. t ¼ 0/63, P,0·05.
kWithin group increase t ¼ 14/63 v. t ¼ 7, P,0·05.
{Within group increase t ¼ 7 v. t ¼ 0, P,0·05.
** Within group increase t ¼ 7 v. t ¼ 0/63, P,0·05.
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The pH of faecal water ranged from 6·3 to 6·7 and did
not differ between groups and within both groups during the
study period.
Discussion
The present double-blind, placebo-controlled, randomised
study demonstrated that the intake of a multispecies probiotic
in this COPD population with a history of frequent antibiotic
use had no effect on the composition of the dominant faecal
microbiota. Moreover, in contrast to previous findings in
healthy volunteers, no effect of antibiotic intake on the
composition of the dominant faecal microbiota could be
found and no difference in SI was observed between the
group of patients who developed diarrhoea-like bowel move-
ments and those who did not. Looking at specific bacterial
subgroups, using both molecular and culture-dependent tech-
niques, a significant but small antibiotic effect was observed
in both the groups, i.e. an increase in yeasts and a decrease
in bifidobacteria. No differences were observed when compar-
ing the probiotic group with the placebo group. However,
changes in specific bacterial groups over time were seen in
the probiotic group only, suggesting a modest probiotic effect.
In healthy human subjects, the faecal microbiota is host
specific and relatively stable over time (SI . 80 %)(5,6). It is
well documented that despite methodological differences,
antibiotic treatment, especially amoxycillin, cephalosporins,
clindamycin or broad-spectrum antibiotics, has a marked
effect on the composition of the intestinal microbiota(8,41,42),
which may result in diarrhoea. In line with these findings,
we have previously shown that amoxycillin intake strongly
affected the composition of the dominant faecal microbiota
in healthy volunteers, indicated by a low mean SI (,52 %)
and a decrease in bacterial richness (i.e. number of bands).
We also showed that a lower stability of the dominant intesti-
nal microbiota (i.e. more disruption) is related to a higher risk
of developing AAD(10). Remarkably, using the same methods,
in the COPD population mean SI were high (.90 %) and both
the SI and the band richness remained stable during and after
antibiotic intake. Moreover, no difference in SI (i.e. disrup-
tion) was observed in the group of patients, who developed
diarrhoea-like bowel movements compared with those who
did not. This unexpected lack of effect on the microbiota
could be attributed to the frequent antibiotic use in the past
by this population. Recently, it has been shown that antibiotic
intake can cause medium and long-term disturbances in
(specific) bacterial populations(9,10). Moreover, as antibiotics
only affect sensitive strains, extensive antibiotic use could
have caused a prolonged narrowing of the diversity into a
dominant faecal microbiota consisting of microbial popu-
lations insensitive to the given antibiotics. This assumption
is further supported by the fact that bacterial band richness
in COPD patients at the start of the study was relatively
low, i.e. being at the same level as in healthy volunteers
during amoxycillin intake, in whom band richness was signifi-
cantly reduced(10). It is known that the bacterial diversity
decreases with age(43), and we readily acknowledge that the
mean age of the patients in the present study was significantly
higher than that of the healthy volunteers in the previous
study. However, this cannot account for the fact that no anti-
biotic effect on bacterial diversity was observed in the COPD
patients. In fact, this finding was corroborated by a similar
trend in endotoxin concentrations. Previously, antibiotics
have been shown to increase the bioavailability of endotoxin
originating from gram-negative bacteria(44 – 47). However, in
our study, we found that endotoxin concentrations remained
stable during and after antibiotic intake and were even slightly
higher than the levels found in healthy volunteers during
amoxycillin intake, where an increase was found(37).
In addition to qualitative data on microbiota composition
obtained by DGGE analysis of 16S rRNA gene fragments,
quantitative analysis of specific bacterial subgroups was per-
formed by culture and quantitative PCR.
With culture, apart from a small but clinically insignificant
rise in yeasts, no changes were observed, that could be attrib-
uted to antibiotic intake. Moreover, with quantitative PCR, no
effect of antibiotic intake was found on total bacteria, which is
in line with the DGGE results. This further supports the lack
of observed antibiotic effect. However, the number of bifido-
bacteria was significantly affected in both the groups during
antibiotic intake corresponding with the reported high suscep-
tibility of bifidobacteria to broad-spectrum antibiotics(48 – 51).
Various effects over time were observed in the probiotic
group only, which can be attributed to probiotic intake. The
increase in faecal enterococci and lactobacilli during probiotic
intake is in line with literature showing that the intake of a
probiotic is able to transiently increase the faecal number of
the ingested strains(52 – 54). We previously showed that the con-
sumption of this multispecies probiotic, containing E. faecium,
was associated with a significant increase in the concentration
of faecal enterococci in the probiotic group and that the
pulsed-field gel electrophoresis patterns of the enterococci cul-
tured were similar to the orally administered E. faecium (37).
Apart from lactobacilli and the E. faecium, the multispecies
probiotic also contained bifidobacteria. However, no increase
in bifidobacteria could be observed, probably due to the fact
that the administered daily amount (2 £ 109 colony forming
units) was too low in relation to the baseline value.
The multispecies product was well tolerated and no adverse
events related to the product were reported. The majority of
literature shows that the probiotics can significantly reduce
the relative risk of developing AAD(19,20,22). In contrast, in
the present study, the intake of the multispecies probiotic
did not result in a decrease in diarrhoea-like bowel move-
ments. However, earlier we showed, in healthy volunteers,
that the intake of the same multispecies probiotic had a restor-
ing and stabilising impact on the dominant faecal microbiota
after amoxycillin intake(10). A comparable observation was
made by Kajander et al. (55), when a multispecies probiotic
was given to irritable bowel syndrome patients. In the present
study, antibiotic intake did not affect the composition of the
dominant microbiota, probably contributing to the lack of
effect of probiotic intake on the occurrence of diarrhoea-like
bowel movements in this COPD population. Furthermore, as
the microbiota seems to be profoundly altered by the frequent
prior antibiotic use, a much longer probiotic treatment might
be required to restore such an effect.
We acknowledge that the present study has some
limitations. Inherent to the nature and severity of the
disease, diverse and extensive medication was used in this
COPD population, and we cannot exclude that some medi-
cation had an impact on the composition of the microbiota.
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Nevertheless, patients had to be on stable medication for cor-
ticosteroids, gastric acid inhibitors and doxycycline mainten-
ance therapy before and during the study to limit this effect.
Although we clearly showed no effect of antibiotic treatment
on the intestinal microbiota due to the heterogeneity of the
population and the limited sample size, subtle changes in sub-
groups’ analyses may have failed to be detected.
Currently, it is widely accepted that antibiotic treatment
profoundly affects the intestinal microbiota. However, our
findings show that the dominant faecal microbiota was not
affected upon antibiotic treatment in COPD patients with a
history of frequent antibiotic use. This prolonged antibiotic
pressure seems to have caused a long-term imbalance of
the microbiota with a shift toward populations resistant to
antibiotics. Furthermore, the present study demonstrates that
the short-term intake of a multispecies probiotic had a
modest effect on the intestinal microbiota, albeit much smaller
than previously observed for healthy adults. Nevertheless, this
did not result in a restoration of the microbiota imbalance and
as a result no reduction in diarrhoea-like bowel movements
was found.
These results warrant further confirmation in studies with
a higher number of patients with higher doses of probiotics
and a longer administration period.
In future studies, it would be very interesting to determine
to what extent these disturbances are permanent, what the
effect of these disturbances is and if probiotic supplementation
is able to either prevent or with prolonged use reverse such
an imbalance.
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